Status:
UNKNOWN
Use of Wharton Jelly in Diabetic Nephropathy
Lead Sponsor:
Sophia Al-Adwan
Collaborating Sponsors:
Jordan University of Science and Technology
An-Najah National University
Conditions:
Diabetic Nephropathies
Eligibility:
All Genders
35-70 years
Phase:
PHASE1
PHASE2
Brief Summary
Wharton Jelly derived Mesenchymal stem cells will be injected in the renal parenchyma of patients with Diabetic Nephropathy
Detailed Description
Mesenchymal stem cells (MSCs) are to be isolated from Umbilical cord Wharton's Jelly obtained after normal full term delivery. Samples will be tested for any bacterial or fungal growth as well as end...
Eligibility Criteria
Inclusion
- Willing and able to provide written informed consent.
- Type 2 diabetes mellitus (DM) for ≥ 3 years.
- Estimated GFR (eGFR) 15-45 ml/min/1.73 m2 by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation on 2 or more consecutive measurements at least 30 days apart within the past 6 months, confirmed by isotope kidney scan.
- Urine protein-to-creatinine ratio (UPCR) ≥ 500 mg/mmol (in spot urine or in 24 hour urine collection) confirmed twice over a period of 6 months.
- Ultrasonographic kidney measurements ≥ 10 cm (for both kidneys).
Exclusion
- Patients with uncontrolled hyper or hypo tension; (systolic pressure \>160, \<100: diastolic pressure \< 60, \>100) on two different occasions.
- Poor diabetic control: Hemoglobin A1c (HbA1c) \> 10%.
- New use of hypoglycemic, antihypertensive and/or lipid lowering agent within the past 6 months.
- Increase in the dose of anti-hypertensive and/or hypoglycemic agent of the previous dose within the past 3 months.
- Current fasting total cholesterol \>300 mg/dl.
- Current fasting total triglycerides \>400 mg/dl.
- History of any cardiovascular events in the past 6 months.
- Pregnancy or lactating.
- Positive screening test for infectious diseases as per baseline work up.
- History of kidney transplant
- Systemic autoimmune disease.
- Receiving immunosuppressant medications.
- Patients with glomerulonephritis or any non-DM related kidney disease.
- Patients with any coagulation disorder.
Key Trial Info
Start Date :
November 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2021
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT03288571
Start Date
November 1 2019
End Date
January 1 2021
Last Update
July 24 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.